3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Recurrence
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Intraoral Tumor
1
Esophageal Neoplasms
1
Disease Progression
1
Chalazion
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Brain Edema
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Sevoflurane
×
Clear all
NCT06330038
2026-04-20
GASTIVA
Samsung Medical Center
Phase 4
Recruiting
5,384 enrolled